ArticleComputational and structural biotechnology journal2021
Dysbiosis and relapse-related microbiome in inflammatory bowel disease: A shotgun metagenomic approach.
Article in Computational and structural biotechnology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Molecular Mechanisms Underlying the Higher Prevalence of Anemia in Crohn's Disease Compared with Ulcerative Colitis: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Microbiome Composition in Microscopic Colitis: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Review
- Microbial, functional, and virulence biomarkers associated with familial risk of Crohn's disease and ulcerative colitis.Biomarker research · 2026Article
- Multiple paths to health: A scoping review of dietary interventions for adults with Crohn's disease and ulcerative colitis.Therapeutic advances in gastroenterology · 2026Article
- Streptococcus mutans exacerbates gut microbiota dysbiosis in SHANK3Journal of oral microbiology · 2026Article
- Health benefits of oat dietary fibre in inflammatory bowel disease: a systematic review.Przeglad gastroenterologiczny · 2026Review
- Gut Microbiota Modulation by Pomegranate Extract: Insights from a Controlled Supplementation Study.Plant foods for human nutrition (Dordrecht, Netherlands) · 2025Article
- Host-microbe multi-omics and succinotype profiling have prognostic value for future relapse in patients with inflammatory bowel disease.Gut microbes · 2025Article
- Single-cell microbiota phenotyping reveals distinct disease and therapy-associated signatures in Crohn's disease.Gut microbes · 2025Article
- Long-term TCDD oral exposure changes gut microbial glycosylation patterns in female but not male C57BL/6 mice.Archives of toxicology · 2025Article
- Article
- A contributory citizen science project reveals the impact of dietary keys to microbiome health in Spain.NPJ biofilms and microbiomes · 2025Article
- Microbiome multi-omics analysis reveals novel biomarkers and mechanisms linked with CD etiopathology.Biomarker research · 2025Article
- Diagnostic Methods and Biomarkers in Inflammatory Bowel Disease.Diagnostics (Basel, Switzerland) · 2025Review
- Improvement of the inflammation-damaged intestinal barrier and modulation of the gut microbiota in ulcerative colitis after FMT in the SHIME® model.BMC complementary medicine and therapies · 2025Article
- A Diet Fortified with Anthocyanin-Rich Extract (RED) Reduces Ileal Inflammation in a Senescence-Prone Mice Model of Crohn's-Disease-like Ileitis.Antioxidants (Basel, Switzerland) · 2025Article
- Comparative analysis of Parkinson's and inflammatory bowel disease gut microbiomes reveals shared butyrate-producing bacteria depletion.NPJ Parkinson's disease · 2025Review
- Gut Microbiota Serves as a Crucial Independent Biomarker in Inflammatory Bowel Disease (IBD).International journal of molecular sciences · 2025Review
- Predicting Risk of Post-Treatment Relapse in Patients with Inflammatory Bowel Disease Based on Intestinal Microbiota.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease (CD) and ulcerative colitis (UC), the two main forms of inflammatory bowel disease (IBD), affect several million people worldwide. CD and UC are characterized by periods of clinical remission and relapse. Although IBD patients present chronic alterations of the gut microbiome, called dysbiosis, little attention has been devoted to the relapse-related microbiome. To address this gap, we generated shotgun metagenomic data from the stools of two European cohorts-134 Spanish (followed up for one year) and 49 Belgian (followed up for 6 months) subjects-to characterize the microbial taxonomic and metabolic profiles present. To assess the predictive value of microbiome data, we added the taxonomic profiles generated from a previous study of 130 Americans. Our results revealed that CD was more dysbiotic than UC compared to healthy controls (HC) and that strategies for energy extraction and propionate production were different in CD compared to UC and HC. Remarkably, CD and UC relapses were not associated with alpha- or beta-diversity, or with a dysbiotic score. However, CD relapse was linked to alterations at the species and metabolic pathway levels, including those involved in propionate production. The random forest method using taxonomic profiles allowed the prediction of CD vs. non-CD with an AUC = 0.938, UC vs. HC with an AUC = 0.646, and CD relapse vs. remission with an AUC = 0.769. Our study validates previous taxonomic findings, points to different relapse-related growth and defence mechanisms in CD compared to UC and HC and provides biomarkers to discriminate IBD subtypes and predict disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.